BD Project | Potential FIC Oncology Project（Anti-IL-18BP Antibody） Looking For Global Partners

BD Project | Potential FIC Oncology Project（Anti-IL-18BP Antibody） Looking For Global Partners

Project ID: DT20220330-002

Asset：Anti-IL-18BP Antibody

Indications: Solid tumors (melanoma, kidney cancer, triple negative breast cancer, non-small cell lung cancer, head and neck squamous cell carcinoma)

Stage: lead – PCC

Several anti-IL-18BP Abs have been identified with high affinity through Elisa binding assay.

Efficacy study in syngeneic mouse model has completed and showed anti-tumor activity.

Highlights:

1. IL-18BP can simultaneously act on CD8+ T cells and NK cells to activate the anti-tumor activity.

2. With first in class potential, own a new mechanism of action and very few similar competitors.

3. The biological mechanism of action is complementary to PD-1/L1. It shows a synergistic effect when combined with PD-1 antibody in animal study. It is expected to be used in combination with PD-1 inhibitors for various solid tumors such as melanoma, kidney cancer, triple negative breast cancer, non-small cell lung cancer, head and neck squamous cell carcinoma. 4. Global patents were filed on Jan, 2022

About The Target:

IL-18 is an important cytokine in the human body, which can regulate both innate and acquired immunity.

IL-18 can promote the maturation and activity of NK cells, expand T cell precursors, stimulate the secretion of IFN-γ by NK cells and T cells, and enhance their immune activity. Existing data shows that IL-18 has a strong anti-tumor effect through the mechanisms above.

IL-18BP, which can bind to IL-18, is a natural inhibitor of IL-18 and a promising therapeutic target for cancer immunotherapy. The high expression of IL-18BP was found in various tumor specimens, and this is one of the mechanisms by which various tumors evade the immune attack.

As anti-IL-18BP antibodies could prevent IL-18BP from binding to IL-18, hence IL-18 can be released to activate the immune response and achieve the purpose of killing tumor cells.

Objectives: Find partners to transfer global rights.

If you are interested in this project, please feel free to contact us.

Contact: Will

E-mail: BD@drugtimes.cn

Please note the project ID: DT20220330-002

We will discuss with you in detail.

Thanks!